Finance

Lists
TNGX:NASDAQ
Tango Therapeutics Inc
$25.02
+0.70%
(+0.17) 1D
Nov 13, 1:50:21 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNGX...
Open
$24.76
High
$25.08
Low
$23.66
Mkt. cap
4.24B
Avg. vol.
4.23M
Volume
919.34K
52-wk high
$34.39
52-wk low
$7.60
EPS
-$1.37
Beta
1.26
Shares outstanding
169.46M
No. of employees
137
Open
$24.76
High
$25.08
Low
$23.66
Mkt. cap
4.24B
Avg. vol.
4.23M
Volume
919.34K
52-wk high
$34.39
52-wk low
$7.60
EPS
-$1.37
Beta
1.26
Shares outstanding
169.46M
No. of employees
137
News stories
From web sources and news partners
About Tango Therapeutics Inc
CEO-
Employees137
Founded2017
HeadquartersBoston, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websitetangotx.com
Analyst ratings
Based on 7 analysts giving stock ratings to TNGX in the past 3 months
Strong buy
Buy
6
Hold
1
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for TNGX in the last 3 months.
Highest
Current $25.02
$67.00 (+167.73%)
Average
$45.14 (+80.38%)
Lowest
$24.00 (-4.10%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
$67.00
+167.7%
11/10/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
$47.00
+87.8%
11/10/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$35.00
+39.9%
11/09/2026
John Newman
Canaccord Genuity
Buy
Maintained
$46.00
+83.8%
11/10/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
$55.00
+119.8%
10/23/2026
Unknown Analyst
William Blair
Buy
Initiated
$42.00
+67.8%
10/15/2026
Alethia Young
William Blair
Buy
Initiated
$42.00
+67.8%
10/15/2026
Sharon Zackfia
William Blair
Buy
Initiated
$42.00
+67.8%
10/15/2026
Kelsey Goodwin
Piper Sandler
Hold
Maintained
$24.00
-4.1%
10/01/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$39.00
+55.8%
08/12/2026
Joseph Catanzaro
Mizuho Securities
Buy
Maintained
$40.00
+59.8%
07/17/2026
Maury Raycroft
Jefferies
Buy
Upgraded
$60.00
+139.8%
06/26/2026
Kalpit Patel
Wolfe Research
Buy
Upgraded
$35.00
+39.9%
06/08/2026
Yuan Zhi
B. Riley Securities
Buy
Reiterated
$35.00
+39.9%
06/09/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$32.00
+27.9%
06/01/2026
Andrew Berens
Leerink Partners
Buy
Reiterated
$55.00
+119.8%
05/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
32.10M
33.53M
37.20M
48.93M
Cost of revenue
32.10M
33.53M
37.20M
48.93M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.76M
15.24M
22.59M
29.19M
Operating expense
9.76M
15.24M
22.59M
29.19M
Total operating expenses
41.86M
48.77M
59.78M
78.12M
Operating income
-41.86M
-48.77M
-59.78M
-78.12M
Other non operating income
3.30M
-45.00K
722.00K
-29.00K
EBT including unusual items
-38.80M
-45.51M
-55.34M
-68.39M
EBT excluding unusual items
-36.88M
-46.64M
-55.34M
-70.99M
Income tax expense
-55.00K
1.00K
1.00K
-
Effective tax rate
0.14%
-
-
-
Other operating expenses
-
-
-
-
Net income
-38.75M
-45.51M
-55.34M
-68.39M
Net profit margin
-
-
-
-
Earnings per share
-0.29
-0.32
-0.37
-0.39
Interest and investment income
1.68M
2.18M
3.72M
7.15M
Interest expense
-
-
-
-
Net interest expenses
1.68M
2.18M
3.72M
7.15M
Depreciation and amortization charges
-
-
-
-
EBITDA
-41.38M
-48.31M
-59.36M
-77.70M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps